The Kangmei Pharmaceutical scandal remains one of China’s most significant corporate fraud cases. It exposed systemic weaknesses in corporate governance and showed the damage that unchecked misconduct can cause to investors, companies and market confidence. The revised Company Law of the People’s Republic of China, adopted in 2023, seeks to strengthen duties and accountability, although questions of enforcement and responsibility remain.
How the Governance Breakdown Happened
The fraud involved inflating profits by billions of yuan and diverting company funds for personal use. The founding family manipulated financial reporting, misappropriated company money and prioritised personal interests over the company. The board failed in its oversight role: some directors approved falsified statements, while others lacked sufficient independence or expertise to identify and challenge the fraud. Senior management, including the Chief Financial Officer, participated in falsifying records and diverting funds. The supervisory board failed to detect or act on warning signs, and external auditors failed to identify discrepancies and, in some cases, were alleged to have colluded with the company.
What the Revised Company Law Changes
Three provisions are particularly relevant. Article 180 sets duties of loyalty and diligence for directors, supervisors and senior executives, requiring them to act in the company’s interests, avoid conflicts and exercise reasonable care. Article 181 prohibits conduct including embezzlement, unauthorised use of company funds and improper disclosure of confidential information. Article 188 provides a framework for liability where directors and senior executives cause loss through misconduct or failure to perform their duties.
The central challenge is not only writing stronger rules, but making responsibility identifiable and enforceable. Overlapping roles, collective versus individual accountability, minority-shareholder protection and consistent judicial interpretation all remain important governance issues.
The Role of D&O Liability Insurance
Directors and Officers (D&O) liability insurance can form part of a practical governance framework. It can protect directors and officers against significant personal financial exposure arising from covered claims; provide defence-cost support in complex disputes; reduce the personal risk attached to board positions; and help companies attract qualified directors. Properly structured D&O insurance is not a substitute for good governance or lawful conduct, but it can provide a safety net for covered mistakes and negligence while supporting a culture of diligence and transparency.
Conclusion
The Kangmei case is a reminder that governance failures rarely occur at only one level. Stronger law, effective boards, independent supervision, competent auditors and appropriate insurance all have roles to play. The revised Company Law strengthens the framework, but lasting improvement depends on consistent enforcement, clear accountability and proactive risk management.
COLACO.TECH